Ingenuity canonical pathway | Minus log ( P-value) | Molecules |
---|---|---|
Axonal guidance signaling | 4.5 | EPHA7, ARHGEF12,SOS2,PTCH1,ITGA5,ROBO1,WNT2,EFNB2,FZD4,IGF1,EFNB1,GNA13,PRKD3,ADAM9,NRP1 |
Role of NANOG in mammalian embryonic stem cell pluripotency | 3.65 | SOX2,LIF,FZD4,GAB1,SOS2,BMPR2,WNT2 |
HGF signaling | 3.07 | ETS1,GAB1,SOS2,MAPK10,ETS2,PRKD3 |
Cholecystokinin/gastrin-mediated signaling | 3.02 | ITPR2,SOS2,MAPK10,RHOU,GNA13,PRKD3 |
Pantothenate and CoA biosynthesis | 2.93 | PANK1,ENPP1,ENPP5 |
Molecular mechanisms of cancer | 2.82 | ARHGEF12,FZD4,GAB1,SOS2,PTCH1,MAPK10,RHOU,BMPR2,HIF1A,GNA13,PRKD3 |
Endothelin-1 signaling | 2.56 | EDNRB,GAB1,ITPR2,MAPK10,MAPK6,GNA13,PRKD3 |
RAR activation | 2.49 | TAF4 RARB,IGFBP3,MAPK10,NCOR1,PRKD3,PPARGC1A |
Mouse embryonic stem Cell pluripotency | 2.37 | SOX2,LIF,FZD4,SOS2,BMPR2 |
Phospholipase C signaling | 2.35 | ARHGEF12,ITPR2,SOS2,RHOU,RPS6KA3,ITGA5,GNA13,PRKD3 |
IGF-1 signaling | 2.31 | CTGF,IGF1,SOS2,IGFBP3,GRB10 |
Hepatic fibrosis/hepatic stellate cell activation | 2.31 | COL1A2,CTGF,IGF1,EDNRB,FLT1,IGFBP3 |
ERK5 signaling | 2.29 | LIF,GAB1,RPS6KA3,GNA13 |
Glioblastoma multiforme signaling | 2.17 | FZD4,IGF1,ITPR2,SOS2,RHOU,WNT2 |
Growth hormone signaling | 2.15 | IGF1,IGFBP3,RPS6KA3,PRKD3 |
GDNF family ligand-receptor interactions | 2.15 | GAB1,ITPR2,SOS2,MAPK10 |
Renal cell carcinoma signaling | 2.11 | ETS1,GAB1,SOS2,HIF1A |